Peptide Drugs advanced
DUAL I Trial
Phase 3 trial demonstrating superiority of degludec-liraglutide over glargine in HbA1c reduction with less hypoglycemia.
By Encyclopeptide Editorial | 1 min read
insulin glp1-combination clinical-trial
DUAL I Trial
Overview
Phase 3 trial demonstrating superiority of degludec-liraglutide over glargine in HbA1c reduction with less hypoglycemia.
Structure
| Property | Value |
|---|---|
| Name | DUAL I Trial |
Mechanism of Action
Co-formulation showed non-inferior HbA1c reduction with significantly less hypoglycemia vs glargine.
References
- Wikipept Peptide Database
- Primary literature (see individual entries)
Chemical Identity
| Property | Value |
|---|---|
| Name | DUAL I Trial |
| Category | Peptide Drugs |
Test Your Knowledge
Reinforce what you learned about DUAL I Trial with interactive quizzes on Wikipept.
Take a Quiz on Wikipept